Kevin Kunzmann

A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?

The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

DARE-19 data show a slight improvement in outcomes among hospitalized COVID-19 patients receiving the SGLT-2 inhibitor—showing the cardiovascular drug class is safe in patients with the pandemic virus.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

Research from ARVO 2021 details the complexities and current challenges faced when attempting to address the burden of diabetic eye disease while the number of patients with diabetes in the US continues to balloon.

Climate change health experts Poune Saberi, MD, and Alan S. Greenglass, MD, join Lungcast for a timely discussion on environmental health issues.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

The innovative technology is associated with significantly improved time to tear breakup, meibum quality, and improved inflammatory markers.

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.